Peregrine Capital Management LLC Trims Holdings in Kiniksa Pharmaceuticals International, plc $KNSA

Peregrine Capital Management LLC trimmed its position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 6.6% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 288,636 shares of the company’s stock after selling 20,554 shares during the period. Peregrine Capital Management LLC owned about 0.40% of Kiniksa Pharmaceuticals International worth $7,987,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its holdings in Kiniksa Pharmaceuticals International by 84.8% in the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company’s stock valued at $27,000 after purchasing an additional 568 shares in the last quarter. US Bancorp DE acquired a new position in shares of Kiniksa Pharmaceuticals International during the 1st quarter valued at about $33,000. Asset Management One Co. Ltd. acquired a new position in shares of Kiniksa Pharmaceuticals International during the 1st quarter valued at about $41,000. Wealthquest Corp acquired a new position in shares of Kiniksa Pharmaceuticals International during the 1st quarter valued at about $42,000. Finally, Robeco Institutional Asset Management B.V. acquired a new position in shares of Kiniksa Pharmaceuticals International during the 2nd quarter valued at about $233,000. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Citigroup increased their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Friday, October 17th. Wells Fargo & Company increased their target price on shares of Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an “overweight” rating in a research report on Thursday, September 25th. Wedbush increased their target price on shares of Kiniksa Pharmaceuticals International from $38.00 to $44.00 and gave the stock an “outperform” rating in a research report on Monday, October 13th. Finally, Jefferies Financial Group increased their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a “buy” rating in a research report on Tuesday, July 29th. Seven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $46.86.

Kiniksa Pharmaceuticals International Stock Up 4.3%

NASDAQ KNSA opened at $40.60 on Tuesday. The stock has a market cap of $3.01 billion, a PE ratio of 1,015.25 and a beta of 0.16. Kiniksa Pharmaceuticals International, plc has a fifty-two week low of $17.82 and a fifty-two week high of $40.89. The business has a 50 day moving average price of $36.56 and a two-hundred day moving average price of $30.63.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, topping analysts’ consensus estimates of $0.18 by $0.05. The firm had revenue of $156.80 million during the quarter, compared to analysts’ expectations of $145.21 million. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%. Sell-side analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Insider Buying and Selling

In other news, COO Eben Tessari sold 138,614 shares of the stock in a transaction that occurred on Tuesday, August 5th. The stock was sold at an average price of $33.20, for a total transaction of $4,601,984.80. Following the completion of the transaction, the chief operating officer directly owned 49,915 shares in the company, valued at approximately $1,657,178. This represents a 73.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CAO Michael R. Megna sold 50,490 shares of the stock in a transaction that occurred on Monday, October 20th. The shares were sold at an average price of $38.87, for a total value of $1,962,546.30. Following the transaction, the chief accounting officer owned 27,046 shares of the company’s stock, valued at approximately $1,051,278.02. This trade represents a 65.12% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 905,298 shares of company stock worth $32,343,574 in the last 90 days. 53.48% of the stock is owned by insiders.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.